Need Help?

Cancer_Cell_Line_Exome_Sequencing_

Genomic characterisation of a large series of cancer cell lines.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001039 Illumina HiSeq 2000 1072
EGAD00001004201 Illumina HiSeq 2000 Illumina HiSeq 2500 75
EGAD00010000644 1022
Publications Citations
A Landscape of Pharmacogenomic Interactions in Cancer.
Cell 166: 2016 740-754
928
Assessment of pharmacogenomic agreement.
F1000Res 5: 2016 825
18
Revisiting inconsistency in large pharmacogenomic studies.
F1000Res 5: 2016 2333
44
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Nat Commun 9: 2018 2024
51
Genetic and transcriptional evolution alters cancer cell line drug response.
Nature 560: 2018 325-330
406
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
BMC Genomics 19: 2018 604
38
The germline genetic component of drug sensitivity in cancer cell lines.
Nat Commun 9: 2018 3385
24
An RNAi screen in human cell lines reveals conserved DNA damage repair pathways that mitigate formaldehyde sensitivity.
DNA Repair (Amst) 72: 2018 1-9
8
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.
Genome Biol 20: 2019 27
20
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569: 2019 503-508
1410
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.
Nat Commun 10: 2019 2198
60
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Nat Commun 10: 2019 2674
127
Copy number variation is highly correlated with differential gene expression: a pan-cancer study.
BMC Med Genet 20: 2019 175
111
Chromosome arm aneuploidies shape tumour evolution and drug response.
Nat Commun 11: 2020 449
43
Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns.
Sci Adv 6: 2020 eaba1862
33
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.
Patterns (N Y) 1: 2020 100065
5
A first-generation pediatric cancer dependency map.
Nat Genet 53: 2021 529-538
53
Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines.
Elife 10: 2021 e66198
6
Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response.
Int J Mol Sci 22: 2021 10135
1
Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
BMC Med 20: 2022 175
3
Mutational signatures are markers of drug sensitivity of cancer cells.
Nat Commun 13: 2022 2926
24
CNpare: matching DNA copy number profiles.
Bioinformatics 38: 2022 3638-3641
2